Clincosm LogoSign in Get a demo

Evaluation of the Causes and Disease Processes of Chronic Lung Disease

Sponsor
National Heart, Lung, and Blood Institute (NHLBI) (NIH)
Overall Status
Completed
CT.gov ID
NCT00001183
Collaborator
(none)
6,564
Enrollment
1
Location
420.9
Actual Duration (Months)
15.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura).

The purpose of this research study is to evaluate patients referred to the Cardiovascular and Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to;

  1. Develop a better understanding of the causes and disease processes involved in disorders of the lungs

  2. Identify patients eligible to participate in other P-CCMB research studies

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other NHLBI protocols. Testing and procedures will only be performed when medically indicated for the purposes of making a diagnosis or obtaining information likely to be useful in the management of the subjects' disease or condition.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    6564 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)
    Actual Study Start Date :
    Nov 18, 1984
    Actual Primary Completion Date :
    Dec 16, 2019
    Actual Study Completion Date :
    Dec 16, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Pulmonary Patients

    Outcome Measures

    Primary Outcome Measures

    1. N/A-screening protocol [1 Visit]

      Evaluate

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    7 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION CRITERIA:

    Symptoms consistent with pulmonary disease.

    May have family history of lung disease.

    Patients with diseases of organs with known association with lung disease.

    Ranging in age from 7 to 90 years old.

    Pregnant and nursing women may participate in minimal risk procedures

    EXCLUSION CRITERIA:

    Persons with no clinical evidence of lung disease.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Heart, Lung, and Blood Institute (NHLBI)

    Investigators

    • Principal Investigator: Joel Moss, M.D., National Heart, Lung, and Blood Institute (NHLBI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    National Heart, Lung, and Blood Institute (NHLBI)
    ClinicalTrials.gov Identifier:
    NCT00001183
    Other Study ID Numbers:
    • 820032
    • 82-H-0032
    First Posted:
    Nov 4, 1999
    Last Update Posted:
    Jun 1, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Heart, Lung, and Blood Institute (NHLBI)
    Computed Tomography
    Fiberoptic Bronchoscopy
    Pulmonary Function Testing
    Cardiopulmonary Exercise Testing
    Allergen Skin Testing
    Additional relevant MeSH terms:
    Lung Diseases

    Study Results

    No Results Posted as of Jun 1, 2022